Isotretinoin reduced inflammation in tufted hair folliculitis, but hair tufting remained.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 28 citations
,
October 2010 in “Targeted Oncology” Trastuzumab may cause tufted hair folliculitis as a side effect.
March 2024 in “Poster presentations” Anifrolumab improves quality of life and reduces steroid use in SLE patients.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
2 citations
,
October 2021 in “Journal of Cosmetic Dermatology” Finasteride is more effective and satisfactory than montelukast for treating moderate acne in women.
5 citations
,
November 2024 in “Journal of Clinical Immunology” Dupilumab effectively controls symptoms in infants with Netherton syndrome.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
June 2026 in “Strathprints: The University of Strathclyde institutional repository (University of Strathclyde)” Topical IKKα inhibitors may help prevent CCS tumours.
4 citations
,
May 2020 in “PLOS ONE” Ingenol mebutate gel changes gene expression related to skin development and immune response in actinic keratosis.
IVIG and dupilumab effectively improved symptoms in a child with Netherton syndrome.
12 citations
,
August 2019 in “Dermatitis” Dupilumab for skin problems might reactivate hair loss in some patients.
March 2026 in “JMIR Dermatology” Interest in JAK inhibitors for alopecia areata increased significantly after FDA approval, highlighting the need for patient education.
2 citations
,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
June 2026 in “Journal of General-Procedural Dermatology & Venereology Indonesia” Tofacitinib effectively improves lichen planus pigmentosus symptoms.
1 citations
,
October 2025 in “Nano Research” A new microneedle patch effectively treats atopic dermatitis by reducing skin stress and restoring immune balance.
5 citations
,
July 2024 in “Archives of Dermatological Research” September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
3 citations
,
August 2024 in “Frontiers in Immunology” Targeting specific biomarkers and immune signals is more effective and safer for treating inflammatory skin diseases.
April 2018 in “Journal of Investigative Dermatology”
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.